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Background: Pharmacists may improve medication-related outcomes during transitions of care. The aim of the
Iowa Continuity of Care Study was to determine if a pharmacist case manager (PCM) providing a faxed discharge
medication care plan from a tertiary care institution to primary care could improve medication appropriateness and
reduce adverse events, rehospitalization and emergency department visits.
Methods: Design. Randomized, controlled trial of 945 participants assigned to enhanced, minimal and usual care
groups conducted 2007 to 2012. Subjects. Participants with cardiovascular-related conditions and/or asthma or
chronic obstructive pulmonary disease were recruited from the University of Iowa Hospital and Clinics following
admission to general medicine, family medicine, cardiology or orthopedics. Intervention. The minimal group
received admission history, medication reconciliation, patient education, discharge medication list and medication
recommendations to inpatient team. The enhanced group also received a faxed medication care plan to their
community physician and pharmacy and telephone call 3–5 days post-discharge. Participants were followed for
90 days post-discharge. Main Outcomes and Measures. Medication appropriateness index (MAI), adverse events,
adverse drug events and post-discharge healthcare utilization were compared by study group using linear and
logistic regression, as models accommodating random effects due to pharmacists indicated little clustering.
Results: Study groups were similar at baseline and the intervention fidelity was high. There were no statistically
significant differences by study group in medication appropriateness, adverse events or adverse drug events at
discharge, 30-day and 90-day post-discharge. The average MAI per medication as 0.53 at discharge and increased to
0.75 at 90 days, and this was true across all study groups. Post-discharge, about 16% of all participants experienced an
adverse event, and this did not differ by study group (p > 0.05). Almost one-third of all participants had any type of
healthcare utilization within 30 days post-discharge, where 15% of all participants had a 30-day readmission. Healthcare
utilization post-discharge was not statistically significant different at 30 or 90 days by study group.
Conclusion: The pharmacist case manager did not affect medication use outcomes post-discharge perhaps because
quality of care measures were high in all study groups.
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Transitions across care settings are a critical time to man-
age medications [1-6]. Up to two-thirds of individuals have
unintended medication discrepancies at admission, and
medication changes made during the hospitalization are
not always conveyed to primary care providers following
discharge. Rehospitalization is particularly important today
as Medicare policy now reduces payments to health sys-
tems for specified conditions where rates do not meet tar-
get goals. Thus, improving care during transitions is
critical. With medications as one important aspect of care
coordination, involving pharmacists in these processes
may be helpful [7-10].
Medication reconciliation has been advocated to re-
duce medication discrepancies [6-8,11], and is defined as
the development of a medication list that is as accurate
as possible, which is compared at admission, transfer or
discharge, to help ensure correct medications at transi-
tions [11]. However, up-to-date discharge medication
lists do not ensure the correct medications are obtained
and used. In fact, two recent reviews examined the im-
pact of medication reconciliation [7,8] and stated that it
alone was not likely to improve post-discharge utilization,
yet it reduced medication discrepancies, potential adverse
drug events and adverse drug events [10,11]. Hesselink
et al. noted that about half the studies showed improve-
ments in adverse events or healthcare utilization post-
discharge and noted the difficulty in comparing interven-
tions across studies because of their complexity, lack of
detail, varying outcomes and variability in study execution
[9]. Thus, numerous well-designed studies have been re-
ported, but the evidence is not consistent, and further
studies are needed to examine how discharge processes
can be improved to achieve optimal outcomes.
We previously reported the methods for the Iowa
Continuity of Care Study [12]. The aim of the Iowa Con-
tinuity of Care Study was to determine if a pharmacist
case manager (PCM) providing a faxed discharge medi-
cation care plan from a tertiary care institution to pri-
mary care could improve medication appropriateness
and reduce adverse events, rehospitalization and emer-
gency department visits. The major goal was to improve
communication links between the tertiary hospital, the
primary care physician and community pharmacists, and
these providers typically received communication from
the institution by mail (primary care physician) or not at
all (community pharmacists). The hypotheses were: (1)
Medication appropriateness will be improved in patients
receiving care from PCM versus usual care; (2) Adverse
drug events (ADE) will be lower post-discharge in pa-
tients receiving care from PCM versus usual care and (3)
Number of readmission, emergency department visits or
unscheduled office visits will be lower in patients receiv-
ing care from PCM versus usual care.Methods
Design
This study was a randomized, controlled trial where par-
ticipants were assigned to one of three study groups in-
cluding enhanced, minimal and control/usual care
conducted from 2007 to 2012 (Figure 1) [12]. This study
was conducted in one Midwestern academic health cen-
ter, and the study was approved by University of Iowa
and University of Michigan Institutional Review Boards.
Subjects
Electronic medical records were reviewed, and individuals
meeting the inclusion criteria were visited in hospital by
trained research assistants to determine eligibility and ob-
tain informed consent. Recruitment occurred Monday-
Friday on four services from 2008 through 2011 and we
talked with 10–12 admitted patients per week who met
the inclusion criteria. Participants were typically enrolled
into the study within 1 day after admission and random-
ized to study group using the statistician-generated
blinded randomization scheme with sequentially num-
bered envelopes. The intervention in the enhanced or
minimal intervention groups began immediately after
randomization with a visit from a study pharmacist and, if
subjects were in the enhanced intervention group, it con-
tinued for 3–5 days post-discharge when participants were
telephoned. Pharmacists were unaware of whether partici-
pants were assigned to the enhanced or minimal interven-
tion group until discharge. For the outcome data, all study
participants were followed for 90 days post-discharge.
Participants were recruited from general medicine,
family medicine, cardiology or orthopedics. The inclu-
sion criteria were English or Spanish speaker, 18 years or
older, admitted with diagnosis of hypertension, hyperlip-
idemia, heart failure, coronary artery disease, myocardial
infarction, stroke, transient ischemic attack, asthma,
chronic obstructive pulmonary disease or receiving oral
anticoagulation. These conditions were focused on in this
study because of previous work we had completed among
patients with cardiovascular conditions where pharmacists
had impacted their clinical outcomes. Individuals were ex-
cluded if they were admitted to psychiatry, surgery or
hematology/oncology service, could not use a telephone,
had life expectancy <6 months, had dementia or cognitive
impairment or had a severe psychiatric diagnosis. These
individuals were excluded because they may have had dif-
ficulty completing all aspects of the study. In addition, par-
ticipants were excluded if they received primary care or
prescriptions from University of Iowa Hospital and Clinics
(UIHC) with shared medical record access. The reason for
this exclusion was to include providers external to UIHC
to determine if the intervention could improve communi-
cation to primary care providers. We randomized 945 par-
ticipants, and 9 participants (3 from each study group)
Figure 1 Iowa Continuity of Care Recruitment and Intervention.
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stopped the trial at 945, as we had attained 95% of the
intended participants and funding was nearing comple-
tion. The study was designed to have 80% power to detect
a between-group effect size of 0.22 standard deviation for
medication appropriateness.
Intervention
A pharmacist case manager (PCM) provided a set of
specified activities for the minimal and enhanced inter-
vention groups, as outlined in Figure 1 [12]. The PCMswere PharmD-trained with pharmacy residency training
or equivalent direct patient care experience. Two investi-
gators (BLC, AJC) trained two PCMs concerning the
intervention, strategies to communicate with inpatient
physicians, primary care physicians and community
pharmacists and methods to improve medication adher-
ence. Over time there was turnover in PCMs, so each
new PCM was trained by the previous intervention
pharmacists by providing care together for several study
participants, with a focus on the intervention activities
and study documentation.
Enhanced
n = 314
Minimal
n = 315
Usual Care
n = 316
311 received intervention
3 found ineligible early in 
the study 
312 received intervention
2 found ineligible early in the study 
1 did not have baseline evaluator 
data
313 received intervention
1 found ineligible early in the study 
2 did not have baseline evaluator 
data
n=311 for primary 
analysis
n=312 for primary 
analysis
n=313 for primary 
analysis
Randomized 945 patients to one of 3 groups
12 deceased
8 lost to follow-up
4 withdrew
5 deceased
8 lost to follow-up
2 withdrew
1 other
7 deceased
5 lost to follow-up
1 withdrew
287 completed the study
296 completed the study
300 completed the study
n=307 for 30 day 
MAI data analysis
n=304 for 30 day 
MAI data analysis 
n=309 for 30 day 
MAI data analysis
Screened 10-12 admitted patient per week 
meeting study inclusion during 2008 to 2011
Figure 2 Iowa Continuity of Care Study Recruitment Chart.
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groups received admission medication reconciliation,
pharmacist visits every 2–3 days for patient education
during inpatient stay, discharge counseling and dis-
charge medication list. For example, counseling was tai-
lored for each participant and focused on goals of
therapy, medication administration, barriers to adher-
ence including cost and patient concerns [12]. Partici-
pants in the enhanced intervention group also received
a telephone call at 3–5 days post-discharge and primary
care physician and community pharmacist received a
discharge care plan focused on medication changes and
recommendations. The care plan was faxed to the pri-
mary care physician and community pharmacist within
24 hours of discharge but usually within 6 hours. The
care plan included the discharge medication list, plans
for dosage adjustments and monitoring, recommenda-
tions for preventing adverse drug events, with patient-
specific concerns such as adherence or cost issues
highlighted. Usual care was medication reconciliation at
admission according to hospital policy, nurse discharge
counseling and a discharge medication list for patients.
The usual care discharge summary was transcribed and
received in the mail by the primary care physician sev-
eral days or weeks after discharge.Data collection
The research assistant gathered baseline data including
demographics, clinical characteristics and medication-
related information [13-17]. The PCM recorded all inter-
ventions. At 30 and 90 days post-discharge, all participants
were phoned by trained research assistants to gather
self-reported adverse events and symptoms and self-
reported healthcare utilization. Primary care provider
and pharmacy records were obtained for all subjects.
Hospitalization records were obtained from the univer-
sity hospital and community hospitals when such an
event occurred.
The primary outcome for the study was medication
appropriateness. The medication appropriateness index
(MAI) was completed by two trained research pharma-
cists (not the intervention pharmacists) who rated the
appropriateness of all medications for all study subjects
using medication lists at discharge, 30 days post-
discharge and 90 days post-discharge [17]. These lists
were obtained from community pharmacy and physician
office records. Each medication was scored 0 for appro-
priate or somewhat appropriate, and 1 for inappropriate
on each of six criteria. These six criteria (weight) in-
cluded indication for medication (3), optimal medication
(3), dose appropriate (2), drug-disease interaction (2),
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tive (1). For each medication, the weighted sum across
the six criteria were calculated, with an MAI range for
each medication of 0 = fully appropriate to 12 = fully in-
appropriate. We calculated the sum per patient and the
average MAI per medication.
Secondary outcomes included adverse events (AEs),
preventable adverse events and a composite variable of
combined hospital readmission, emergency department
visit or unscheduled office visit during the 30-day and
90-day follow-up period. We determined adverse events
arising from lack of medications, either non-adherence
or under-treatment, and adverse drug events arising
from medication exposures [18,19]. The trained research
pharmacists reviewed all records including hospital dis-
charge summary, primary care records, pharmacy re-
cords and 30-day and 90-day telephone calls to identify
symptomatology which we termed potential adverse
events. The research pharmacists then rated four ques-
tions for each potential adverse event to determine the
confidence that the symptoms arose from patient non-
adherence, under-treatment or medication exposure and
the final question asked about preventability. For medi-
cation exposure, a Naranjo score was calculated from
ten items to determine the extent to which symptoms
may be related to medications [20]. The research phar-
macists’ ratings to these questions were reviewed by a
team of physician and pharmacist to confirm the ratings.
In the analysis, only AEs or ADEs with virtual certainty
or strong level of confidence or a Naranjo score of 5 or
greater was counted. The number of AEs and ADEs for
each subject was determined, and each AE and ADE was
labeled as preventable if the preventability rating was
definite or probable.
Finally, we counted the number of occurrences of hos-
pital readmission, emergency department visits and un-
scheduled office visits using patient self-report and
physician and hospital records.
Analysis
Descriptive statistics were calculated for the demograph-
ics, clinical characteristics and the study outcomes. The
fidelity of pharmacist interventions was compared be-
tween minimal and enhanced groups using the chi-
square test for categorical variables and t-tests for nu-
meric variables. Preliminary analyses accommodating
random effects due to pharmacists indicated very little,
if any, clustering within pharmacist, so standard regres-
sion methods were used to analyze the study outcomes.
For the case of MAI and MAI per medication, linear re-
gression was performed on the square root scale to im-
prove normality. The other outcomes were dichotomous
and analyzed using logistic regression. Since the minimal
and enhanced interventions were identical until patientdischarge, comparisons were made with both intervention
groups combined versus the control group at discharge.
For post-discharge comparisons, each intervention group
was compared to the control group. We performed a sub-
group analysis including only those who had heart failure
or asthma/pulmonary disease using the same analytic ap-
proach as described above.
Results
We enrolled 945 participants into the study (Figure 2),
and study groups were comparable at baseline (Table 1).
The mean age (±SD) of participants in the study was 61.0
(±12.2) years, with 91% white and 66% married or living as
married. The income and education distributions showed
that 47% of study participants had an annual income less
than $40,000 and 49% had a high school education, re-
spectively. Most participants in the study had health insur-
ance, with almost half having private insurance. Almost
all, 96%, had prescription drug insurance.
Participants were similar in terms of chronic conditions,
smoking status and alcohol intake at baseline, though
baseline medications were slightly higher in the minimal
intervention group compared to controls (p = 0.0009)
(Table 1). The prevalence of chronic kidney disease and
reporting never or rarely forgetting to take medications
did vary by study group. More participants in the control
group (85.6%) rarely forgot their medications compared to
minimal (79.0%) and enhanced (75.2%) (p < 0.0046). Self-
rated health was comparable across the study groups, and
13% rated their health as poor, 27% as fair, 40% as good
and 21% were very good or excellent.
Intervention fidelity was high for admission medication
reconciliation and wallet card, but was variable for other
parts of the intervention (Table 2). Discharge counseling
was provided to 75% of enhanced and minimal interven-
tion participants. Among the enhanced intervention group,
84% had their care plan faxed to their community physi-
cians and 80% had it faxed to community pharmacists. Five
pharmacists delivered the PCM activities over the study
period, and their average time spent on study activities var-
ied from 83 (±26) to 202 (±112) minutes per patient per
pharmacist (p < 0.0001). As expected, pharmacists spent
considerably more time with enhanced versus minimal
participants (p < 0.0001).
The average MAI per medication as 0.53 at discharge
and increased to 0.75 at 90 days, and this was true across
all study groups (Table 3). There were no statistically sig-
nificant differences in MAI supporting the intervention.
The control group had a statistically significantly lower
(improved) total MAI at discharge compared to minimal
and enhanced groups, but the average MAI per medica-
tion was not different.
Post-discharge, about 16% of all participants experienced
an AE, and this did not differ by study group (p > 0.05)
Table 1 Participant demographic and clinical characteristics
Enhanced Minimal Control Total
N = 311 N = 312 N = 313 (n = 936)
Age
≤44 years 34 (10.9) 38 (12.2) 29 (9.3) 101 (10.8)
45–54 years 43 (13.8) 52 (16.7) 49 (15.7) 144 (15.4)
55–64 years 101 (32.5) 96 (30.8) 110 (35.1) 307 (32.8)
65–74 years 85 (27.3) 85 (27.2) 85 (27.2) 255 (27.2)
≥75 years 48 (15.4) 41 (13.1) 40 (12.8) 129 (13.8)
Education
Less than high school (1–8) 16 (5.1) 12 (3.9) 22 (7.0) 50 (5.3)
High school (9–12) 151 (48.6) 153 (49.0) 151 (48.2) 455 (48.6)
Some college 66 (21.2) 73 (23.4) 59 (18.9) 198 (21.2)
College degree 45 (14.5) 41 (13.1) 54 (17.3) 140 (15.0)
Professional or advanced degree 33 (10.6) 33 (10.6) 27 (8.6) 93 (9.9)
Race
White 287 (92.3) 283 (90.7) 285 (91.1) 855 (91.4)
African American 12 (3.9) 16 (5.1) 18 (5.8) 46 (4.9)
Hispanic 7 (2.3) 8 (2.6) 6 (1.9) 21 (2.2)
Other 5 (1.6) 5 (1.6) 4 (1.3) 14 (1.5)
Annual income
<$10,000 32 (10.4) 34 (11.0) 35 (11.2) 101 (10.9)
$10,000 - $24,999 55 (17.8) 56 (18.1) 64 (20.5) 175 (18.8)
$25,000 - $39,999 68 (22.0) 53 (17.1) 42 (13.5) 163 (17.5)
$40,000 - $54,999 56 (18.1) 46 (14.8) 42 (13.5) 144 (15.5)
$55,000 and greater 98 (31.7) 121 (39.0) 129 (41.4) 348 (37.4)
Missing 2 2 1 5
Marital status
Single/never married 21 (6.8) 18 (5.8) 29 (9.3) 68 (7.3)
Married or living as married 194 (62.6) 213 (68.3) 206 (65.8) 613 (65.6)
Divorced/separated 56 (18.1) 49 (15.7) 51 (16.3) 156 (16.7)
Widowed 39 (12.6) 32 (10.3) 27 (8.6) 98 (10.5)
Medical service
Internal Medicine/Family Medicine 79 (25.4) 84 (26.9) 84 (26.8) 247 (26.4)
Cardiology 111 (35.7) 111 (35.6) 112 (35.8) 334 (35.7)
Orthopedics 121 (38.9) 117 (37.5) 117 (37.4) 355 (37.9)
Type of medical insurance
Private 157 (50.5) 145 (46.5) 158 (50.5) 460 (49.2)
Medicare 120 (38.6) 123 (39.2) 114 (36.4) 357 (38.1)
Medicaid 27 (8.7) 39 (12.5) 38 (12.1) 104 (11.1)
Other insurer/none/self-pay 7 (2.3) 5 (1.6) 3 (1.0) 15 (1.6)
Prescription drug insurance
Yes 297 (95.5) 294 (94.5) 303 (97.1) 894 (95.7)
Average number of prescription medications* 11.0 (5.7) 11.8 (6.0) 10.4 (5.5) 11.0 (5.8)
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Table 1 Participant demographic and clinical characteristics (Continued)
Chronic conditions (% yes)
Hypertension 249 (80.1) 231 (74.0) 239 (76.4) 719 (76.8)
Hyperlipidemia 194 (62.4) 195 (62.5) 189 (60.3) 578 (61.8)
Heart failure 85 (27.3) 91 (29.2) 76 (24.3) 252 (26.9)
Coronary artery disease 114 (36.7) 108 (34.6) 94 (30.0) 316 (33.8)
Myocardial infarction 69 (22.2) 68 (21.8) 62 (19.8) 199 (21.2)
Transient ischemic attacks 26 (8.4) 30 (9.6) 26 (8.3) 82 (8.8)
Stroke 12 (3.9) 17 (5.5) 14 (4.5) 43 (4.6)
Depression 105 (33.8) 105 (33.7) 98 (31.3) 308 (32.9)
Anxiety 91 (29.3) 79 (25.3) 73 (23.3) 243 (26.0)
Arthritis 193 (62.1) 197 (63.1) 192 (61.3) 582 (62.2)
Diabetes 113 (36.3) 123 (39.4) 114 (36.4) 350 (37.4)
Kidney disease* 35 (11.3) 58 (18.6) 34 (10.9) 127 (13.6)
Liver disease 15 (4.8) 17 (5.5) 14 (4.5) 46 (4.9)
Asthma or pulmonary disease 79 (25.4) 90 (28.9) 86 (27.5) 255 (27.2)
Knee replacement 82 (26.4) 70 (22.4) 78 (24.9) 230 (24.6)
Hip replacement 49 (15.8) 36 (11.5) 32 (10.2) 117 (12.5)
Fracture 135 (43.4) 133 (42.6) 131 (41.9) 399 (42.6)
Cancer 56 (18.0) 54 (17.3) 49 (15.7) 159 (17.0)
Other 172 (55.3) 183 (58.7) 171 (54.6) 526 (56.2)
Smoking status
Never 132 (42.4) 150 (48.1) 126 (40.3) 408 (43.6)
Current 33 (10.6) 35 (11.2) 27 (8.6) 95 (10.2)
Ex-smoker 146 (47.0) 127 (40.7) 160 (51.1) 433 (46.3)
Alcohol intake
None 200 (64.3) 190 (60.9) 183 (58.7) 573 (61.3)
<1 drink/day 82 (26.4) 95 (30.5) 100 (32.1) 277 (29.6)
1–2 drinks/day 22 (7.1) 21 (6.7) 24 (7.7) 67 (7.2)
≥3 drinks/day 7 (2.3) 6 (1.9) 5 (1.6) 18 (1.9)
Self-rated health
Excellent 15 (4.8) 13 (4.2) 19 (6.1) 47 (5.0)
Very good 55 (17.7) 44 (14.1) 48 (15.3) 147 (15.7)
Good 116 (37.4) 122 (39.1) 132 (42.2) 370 (39.6)
Fair 88 (28.4) 87 (27.9) 79 (25.2) 254 (27.2)
Poor 36 (11.6) 46 (14.7) 35 (11.2) 117 (12.5)
Self-reported medication adherence
Forget (% never or rarely)* 233 (75.2) 245 (79.0) 267 (85.6) 745 (79.9)
Careless (% never or rarely) 282 (91.0) 289 (93.2) 299 (95.8) 870 (93.4)
Stop if feel better (% never or rarely) 292 (94.2) 292 (94.2) 302 (96.8) 886 (95.1)
Stop if feel worse (% never or rarely) 278 (89.7) 278 (89.7) 286 (91.7) 842 (90.3)
Medication management ability
Able (% scoring 5) 203 (66.3) 218 (70.1) 211 (68.5) 632 (68.3)
Some limitation (% 4 or less) 103 (33.7) 93 (29.9) 97 (31.5) 293 (68.3)
Missing 5 1 5 11
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Table 1 Participant demographic and clinical characteristics (Continued)
Medication self-efficacy scale
Average (standard deviation) 123.3 (±12.5) 124.4 (±12.3) 125.0 (±10.1) 124.2 (±11.7)
Instrumental activities of daily living
No limitation 215 (69.4) 226 (72.4) 239 (76.4) 680 (72.7)
Requires help or unable on 1 35 (11.3) 42 (13.5) 27 (8.6) 104 (6.0)
Requires help or unable on 2 22 (7.1) 13 (4.2) 21 (6.7) 56 (6.0)
Requires help or unable on 3 or more 38 (12.2) 31 (9.9) 26 (8.3) 95 (10.1)
*Variables were significantly different among groups (p < 0.01).
Table 2 Fidelity of pharmacists’ interventions
Enhanced Minimal P-values
n = 311 n = 312
Admission medication reconciliation 311 (100%) 312 (100%)
Community pharmacy contacted 300 (96.5%) 305(97.8%) 0.34
Discharge counseling completed 235 (75.6%) 235 (75.3%) 0.94
Wallet card completed 309 (99.4%) 308 (98.7%) 0.41
Medication issues identified in hospital 275 (88.4%) 249 (79.8%) 0.003
Post-discharge phone call completed 301 (96.8%) 4 (1.3%)*
Discharge care plan faxed to community physician 267 (85.9%) 1 (0.3%)*
Discharge care plan faxed to community pharmacist 246 (79.1%) 1 (0.3%)*
Discharge care plan included medication recommendations to community
physician
207 (66.6%) NA
Discharge care plan medication issues identified by pharmacists† To Hospital & Community
Physicians
To Hospital
Physicians
Mean (±SD) 6.6 (±6.8) 3.2 (±4.0)
Total number of issues identified 2063 1012
Dosing or administration 260 131
Indication 754 363
Efficacy 319 101
Cost 103 38
Risk to patient 627 379
Discharge care plan recommendations made to physicians† To Hospital & Community
Physicians
To Hospital
Physicians
Mean (±SD) 7.1 (±6.6) 3.5 (±3.8)
Total number of recommendations 2220 1077
Discontinue medications 377 195
Add medications 566 256
Change medications 361 151
Disease monitoring 280 56
Follow-up patient 262 134
Patient education 283 239
Adherence education 91 46
Time pharmacist spent on each patient (minutes) 210.0 (±93.0) 118.5 (±58.6) <.0001
*Inadvertent crossover since care plans should not have been sent according to randomization.
†Many but not all medication issues and recommendations were repeated to the community physicians, accounting for almost twice the numbers in the
enhanced group.
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Table 3 Medication Appropriateness Index (MAI) by study group
Enhanced Minimal Control P-values*
Summed MAI per Participant
Discharge 7.1 (±7.0) 8.0 (±8.4) 6.1 (±6.6) E + M vs. C: 0.03
30 days post-discharge 10.1 (±8.9) 11.7 (±11.2) 9.6 (±9.5) E vs. C: 0.78
M vs. C: 0.07
90 days post-discharge 11.6 (±10.5) 13.6 (±12.3) 11.1 (±11.3) E vs. C: 0.94
M vs. C: 0.02
MAI per Medication
Discharge 0.52 (±0.53) 0.55 (±0.57) 0.51 (±0.54) E + M vs. C: 0.26
30 days post-discharge 0.62 (±0.50) 0.69 (±0.61) 0.65 (±0.57) E vs. C: 0.86
M vs. C: 0.70
90 days post-discharge 0.72 (±0.68) 0.80 (±0.65) 0.73 (±0.63) E vs. C: 0.84
M vs. C: 0.33
*E = enhanced, M =minimal and C = control groups.
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had more AE and ADEs during hospitalization identified
than controls (4.5%), but the difference was not statistically
significant.
About 29% of all participants had any type of health-
care utilization within 30 days post-discharge, where
15% of all participants had a 30-day readmission. There
were no statistically significant differences by study
group for any utilization outcomes (Table 5). We exam-
ined the study participants with CHF and/or asthma/
COPD separately, and the results were consistent with
our overall findings (data not shown).
Discussion
The pharmacist case manager did not affect medication
appropriateness, number of clinically-relevant adverse
events or adverse drug events or post-discharge health-
care utilization. These findings might be explained by
the overall good medication appropriateness and gener-
ally low re-hospitalizations, ED visits and unscheduled
office visits in all study groups when compared to previ-
ous studies. Other studies that have evaluated PCMs had
mixed results, but our methodology and measures were
anticipated to be sensitive to the intervention given pre-
vious findings about pharmacists’ impact post-discharge
[10]. Our finding is important given our strong study de-
sign, subjects with high medication use and a compre-
hensive assessment of all study outcomes.
Our primary outcome was medication appropriateness
and we had good power to detect meaningful differences
based on prior studies (17). Our study was powered to
detect effect sizes of 0.22 in the MAI, but the largest ef-
fect size seen was 0.21 for minimal vs. control at 90 days,
and this was in the wrong direction (minimal having a
higher value). Moreover, the MAI per medication rangedfrom 0.51 to 0.8, indicating high medication appropriate-
ness across the study. These finding suggest very good
medication appropriateness with limited opportunity for
improvement regardless of the intervention.
Our process to determine adverse events and adverse
drug events was comprehensive using patient self-report
of symptomatology along with patient medical records
and expert opinion to establish attribution [18-20]. For-
ster and colleagues evaluated ADEs after discharge [21].
Of 400 patients, 45 (11%) had an ADE and over half
could have been prevented or ameliorated. These ADEs
occurred in spite of electronic discharge summaries be-
ing transmitted to primary care physicians. In our study,
about 16% of all participants experienced an adverse
event within the 90-day post-discharge period that was
virtually certain or highly likely attributed to medica-
tions. While an interim analysis showed that medication
discrepancies were reduced in the enhanced group, and
the medication list in the primary care physician office
was more likely to be up-to-date compared to the min-
imal or control groups [22], this finding did not translate
into other findings.
Between 2008 and 2010 the readmission at the study
hospital were 18.2 and 19.1%, respectively, when our
study was conducted [23]. However, the 30-day readmis-
sion rate among study participants ranged from 13.4% to
16.7%, which is lower than anticipated when the study
was designed. These observations would suggest that the
rate of re-hospitalizations had dropped substantially
after the study was designed which made it difficult for
the intervention to improve these rates. There is con-
flicting evidence from other studies whether 30-day re-
admission rates were declining overall during our study
period 2007–2012. Findings in the Veterans Affairs insti-
tutions suggest a decreasing trend over the past decade,
Table 4 Adverse Events (AE) from non-adherence and under-treatment and Adverse Drug Events (ADE) by study group
Enhanced Minimal Control P-values*
Initial Hospitalization n = 311 n = 312 n = 313
Number of possible adverse events 40 43 40
Number of AEs due to medication non-adherence† 9 9 6
Number of AEs due to medication under-treatment† 1 3 3
Number of ADEs† 15 16 15
Percent of participants with any AE or ADE† 18 (5.8%) 19 (6.1%) 22 (7.0%) E + M vs. C: 0.52
During Hospitalization
Number of possible adverse events 55 52 57
Number of AEs due to medication non-adherence † 1 2 0
Number of preventable medication non-adherence AEs‡ 1 2 0
Number of AEs due to medication under-treatment † 2 0 1
Number of preventable medication under-treatment AEs‡ 2 0 1
Number of ADEs† 18 27 16
Number of preventable ADEs‡ 0 3 1
Percent of participants with any AE or ADE† 19 (6.1%) 19 (6.1%) 14 (4.5%) E + M vs. C: 0.31
Post-Discharge n = 306 n = 309 n = 311
Number of possible adverse events 183 180 174
Number of AEs due to medication non-adherence† 15 8 10
Number of preventable medication non-adherence AEs‡ 15 7 9
Number of AEs due to medication under-treatment† 10 13 6
Number of preventable medication under-treatment AEs‡ 6 11 5
Number of ADEs† 47 49 60
Number of preventable ADEs‡ 8 7 9
Percent of participants with any AE or ADE† 48 (15.7%) 50 (16.2%) 53 (17.0%) E vs. C: 0.72
M vs. C: 0.95
*E = enhanced, M =minimal and C = control groups.
†Medication non-adherence and under-treatment were labeled adverse events (AEs) and counted only if the rating was “Virtually certain” or “Strong level of
confidence”. ADEs were counted only if the Naranjo score was 5 or greater.
‡AEs and ADEs were considered preventable if the rating was “Definitely preventable” or “Probably preventable”.
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ficiaries from 2007 through 2011, until 2012 when rates
declined [23-25]. Focusing this intervention exclusively
on individuals with high risk for readmission post-
discharge would have been a better strategy, yet our sub-
analysis for heart failure showed no differences. Finally,
a broader view of health and functional status besides
medications is likely necessary to further reduce read-
missions. For example, medications are one component
of the Care Transitions Intervention, but it is not the
solitary focus [26].
The content of the PCM intervention was multi-faceted
not merely medication reconciliation. There was some
variability in the delivery of the intervention by the PCMs,
but almost all participants were provided a medication
reconciliation at admission and discharged medication
lists. The PCM was expected to improve medication useat discharge via medication reconciliation and recommen-
dations to the inpatient team. During study initiation, pol-
icy changed at the study hospital and many usual care
patients received admission medication reconciliation.
While the PCM contacted the community pharmacist for
almost all participants at baseline in the minimal and en-
hanced groups, we cannot establish the effect of this call.
As well, the discharge care plan was faxed to 86% of par-
ticipants’ community physicians, and only 66% contained
specific medication recommendations. These two facets of
the intervention may have reduced its effectiveness.
Numerous studies have shown a positive impact of phar-
macists’ recommendations when they work directly with
teams [27-34]. In considering the lack of effect at dis-
charge, the PCMs were study pharmacists and not part of
the inpatient medical teams. Our interim analysis showed
that about half of the pharmacists’ recommendations were
Table 5 Hospital readmission, emergency department visits or unscheduled office visits by study group
Enhanced Minimal Control *P-values
Number of patients with any post-discharge healthcare use
30 days 81 (28.8%) 88 (29.5%) 87 (29.6%) E vs. C: 0.82
M vs C: 0.92
90 days 97 (34.5%) 90 (30.5%) 88 (29.9%) E vs. C: 0.20
M vs C: 0.62
Number of patients with at least one specific post-discharge healthcare use
30 day readmission 47(16.7%) 40 (13.4%) 43 (14.6%) E vs. C: 0.29
M vs C: 0.38
30 day emergency dept visit 38 (13.5%) 49 (16.5%) 52 (17.8%) E vs. C: 0.18
M vs C: 0.71
30 day unscheduled visit 31 (11.0%) 30 (10.1%) 32 (10.9%) E vs. C: 0.81
M vs C: 0.69
90 day readmission 49 (17.4%) 51 (17.3%) 47 (16.0%) E vs. C: 0.77
M vs C: 0.83
90 day emergency dept visit 41 (14.6%) 40 (13.6%) 46 (15.7%) E vs. C: 0.99
M vs C: 0.54
90 day unscheduled visit 42 (15.0%) 36 (12.2%) 33 (11.3%) E vs. C: 0.18
M vs C: 0.74
*E = enhanced, M =minimal and C = control groups.
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ting [35] and the recommendations did not change the
prescribing of cardiovascular medications [36]. Anec-
dotally, inpatient physicians often were reluctant to accept
recommendations for chronic conditions, e.g. hyperlipid-
emia or diabetes, when these were not the reason for the
hospitalization. These findings were disappointing, and
the low rate of accepted recommendations is counter to
pharmacists’ contribution to improved outcomes in both
inpatient and primary care settings [27-34].
The medication care plan and the 3–5 day post-discharge
telephone call were expected to have an impact post-
discharge. About 86% of participants had the discharge care
plan faxed to physicians and almost all participants in the
enhanced intervention group received the post-discharge
telephone follow-up. While over 2000 recommendations
were in the care plans, about one-half of these were pro-
vided to community physicians. Many of the recommenda-
tions were related to adding, changing or discontinuing
medications. Physicians in the community may have not
been aware of the hospitalization until a follow-up visit was
done post-discharge. At that time, a discharge summary
and/or the medication care plan could have been reviewed,
but we have no conclusive way to know whether that oc-
curred. There was no verbal hand-off back to the commu-
nity providers. The development of a discharge medication
care plan and sharing the care plan with physicians via fax
were insufficient to improve medication use or patient out-
comes. A verbal hand-off to physicians was effective in twoprevious studies, suggesting this contact may be critical
[37,38]. However, the best time to actually complete the
verbal hand-off to the primary care physician is unclear, as
the timing would likely be best when the provider is sched-
uled to see the discharged patient. Further, the telephone
follow-up, although provided to almost all intended partici-
pants at 3–5 days post-discharge, was not sufficient to im-
prove outcomes for this population.
Finally, the study population was younger than many
other studies where care transition programs have been
effective [9,26]. Many of the individuals may not have
had a high enough acuity to require such support during
their transition, as about 70% had no instrumental activ-
ity of daily living limitation, only 40% rated their health
as fair or poor, few reported intentional medication non-
adherence, 25% reported forgetting medications and
most participants had high medication self-efficacy. In
retrospect, we should have focused this care transition
intervention towards individuals with transition issues
rather than those where pharmacists had been successful
impacting outcomes in previous studies. In consider-
ation of other studies and our current findings, we sug-
gest that medication-focused care transition activities be
targeted to individuals with greater health acuity who
are known to exhibit medication management difficul-
ties. In addition, implementation of medication-related
recommendations will require more intense interven-
tions than fax from the tertiary hospital with the primary
care physicians after discharge.
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cing hospital readmissions. Hospitals will need to evaluate
the most efficient and effective methods to reduce re-
admissions and reduce adverse events. Improved informa-
tion technology may be useful in transmitting discharge
care plan information more efficiently, but it appears likely
that a verbal or electronically verified hand-off may be ne-
cessary [37,38]. Such an approach would help ensure that
important issues requiring follow-up were specifically
identified for community providers. However, the most ef-
fective strategy may be stronger relationships and commu-
nications with care navigators or primary care physicians
to optimize medications since it is hospitals that are at risk
for re-admissions.
This study has limitations. At baseline, forgetting med-
ications was not well randomized. Yet, it is unlikely that
this single aspect of medication management would
change the impact of the intervention on medication ap-
propriateness or adverse events to a great degree across
the three study groups. The intervention fidelity was
good but not without some issues. We cannot separate
the effect of any specific component of the intervention
such as patient counseling on the outcomes of the study.
We failed to determine whether community physicians
actually used the discharge medication care plan infor-
mation that was sent, and this is an important missing
link in the process of care and in this study. As well, fac-
tors such as pharmacist personalities and health-system
relationships with non-health system primary care pro-
viders form an important context in which such studies
are completed and these cannot be ignored when consid-
ering generalizability. We did not separate self-reported
versus medically document post-discharge events, which
may contribute to measurement error making it more dif-
ficult to detect an effect.
Conclusions
In conclusion, a pharmacist case manager providing ad-
mission medication reconciliation, in-patient medication
recommendations to the hospital team, patient educa-
tion, post-discharge information to community physi-
cians and post-discharge telephone call to patients did
not affect medication appropriateness, adverse events or
post-discharge healthcare utilization.
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